Abstract

BackgroundA high rate of glycolysis leading to elevated lactate content has been linked to poor clinical outcomes in patients with head and neck and cervical cancer treated with radiotherapy. Although the biological explanation for this relationship between lactate and treatment response remains unclear, there is a continued interest in evaluating strategies of targeting metabolism to enhance the effectiveness of radiotherapy. The goal of this study was to investigate the effect of metabolic-targeting through HIF-1α inhibition and the associated changes in glycolysis, oxygen consumption and response on the efficacy of high-dose single-fraction radiotherapy (HD-SFRT).MethodsHIF-1α wild-type and HIF-1α knockdown FaDu and ME180 xenograft tumors were grown in the hind leg of mice that were placed in an environmental chamber and exposed to different oxygen conditions (air-breathing and hypoxia). Ex vivo bioluminescence microscopy was used to measure lactate and ATP levels and the hypoxic fraction was measured using EF5 immunohistochemical staining. The oxygen consumption rate (OCR) in each cell line in response to in vitro hypoxia was measured using an extracellular flux analyzer. Tumor growth delay in vivo was measured following HD-SFRT irradiation of 20 Gy.ResultsTargeting HIF-1α reduced lactate content, and increased both oxygen consumption and hypoxic fraction in these tumors after exposure to short-term continuous hypoxia. Tumors with intact HIF-1α subjected to HD-SFRT immediately following hypoxia exposure were less responsive to treatment than tumors without functional HIF-1α, and tumors irradiated under air breathing conditions regardless of HIF-1α status.ConclusionsBlocking the HIF1 response during transient hypoxic stress increased hypoxia, reduced lactate levels and enhanced response to HD-SFRT. This strategy of combining hypofractionated radiotherapy with metabolic reprogramming to inhibit anaerobic metabolism may increase the efficacy of HD-SFRT through increased oxygen consumption and complementary killing of radiosensitive and hypoxic, radioresistant cells.

Highlights

  • A high rate of glycolysis leading to elevated lactate content has been linked to poor clinical outcomes in patients with head and neck and cervical cancer treated with radiotherapy

  • A high rate of glycolysis leading to high tumor lactate concentration has been linked to poor clinical outcomes in patients with head and neck or cervical cancer treated with fractionated radiotherapy [3, 4] and impaired response to radiation treatment in pre-clinical studies [5]

  • Hypoxia inducible factor 1α (HIF-1α) knockdown HIF-1α KD was observed in both cell types, FaDu and ME180 (Fig. 2a and b)

Read more

Summary

Introduction

A high rate of glycolysis leading to elevated lactate content has been linked to poor clinical outcomes in patients with head and neck and cervical cancer treated with radiotherapy. It has been estimated that over 60% of tumors predominately utilize glycolysis for energy production and survival [1] This shift to a glycolytic metabolism from oxidative phosphorylation was first described eighty years ago by Warburg who observed that cancer cells have high rates of glycolysis even in the presence of high oxygen [2]. A high rate of glycolysis leading to high tumor lactate concentration has been linked to poor clinical outcomes in patients with head and neck or cervical cancer treated with fractionated radiotherapy [3, 4] and impaired response to radiation treatment in pre-clinical studies [5]. Studies have found that lactate itself may directly affect radiation response through free radical scavenging by pyruvate [7, 8] Taken together, these observations suggest that inhibiting glycolysis and lactate production may sensitize tumors to radiotherapy and improve clinical outcomes in patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call